Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field

European Neuropsychopharmacology

Volumn 26, Issue 12, 2016, Pages 1845-1867

  Miskowiak, K W ^a   Ott, C V ^a   Petersen, J Z ^a   Kessing, L V ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Antidepressants; Cognition; Cognitive dysfunction; Pharmacological treatment; Psychological treatment; Unipolar disorder

Indexed keywords

APOMORPHINE; CITALOPRAM; DONEPEZIL; DULOXETINE; ERYTHROPOIETIN; GALANTAMINE; IMIPRAMINE; METFORMIN; MOCLOBEMIDE; NOMIFENSINE; REBOXETINE; VORTIOXETINE;

COGNITION; COGNITIVE DEFECT; COGNITIVE REMEDIATION THERAPY; DISEASE SEVERITY; HUMAN; MAJOR DEPRESSION; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; REVIEW; SYSTEMATIC REVIEW; TAI CHI; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; COMPLICATION; DEPRESSION; META ANALYSIS; METHODOLOGY; PSYCHOLOGY; SELECTION BIAS;

COGNITIVE DYSFUNCTION; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELECTION BIAS; TRANSCRANIAL DIRECT CURRENT STIMULATION;

EID: 84991275691     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.09.641     Document Type: Review

References (71)

1. Antypa, N., Smelt, A.H., Strengholt, A., Van der Does, A.W., Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J. Psychopharmacol. 26:5 (2012), 738–743, 10.1177/0269881111424928.
2. Austin, M.-P., Mitchell, P., Hadzi-Pavlovic, D., Hickie, I., Parker, G., Chan, J., Eyers, K., Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. Psychiatry Res. 97:2–3 (2000), 207–215, 10.1016/S0165-1781(00)00222-5.
3. Baune, B.T., Renger, L., Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – a systematic review. Psychiatry Res. 219:1 (2014), 25–50, 10.1016/j.psychres.2014.05.013.
4. Bora, E., Harrison, B.J., Yucel, M., Pantelis, C., Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol. Med. 43:10 (2013), 2017–2026, 10.1017/S0033291712002085.
5. Bortolato, B., Miskowiak, K.W., Köhler, C.A., Maes, M., Fernandes, B.S., Berk, M., Carvalho, A.F., Cognitive remission: a novel objective for the treatment of major depression?. BMC Med., 14(1), 2016, 10.1186/s12916-016-0560-3.
6. Bowie, C.R., Gupta, M., Holshausen, K., Jokic, R., Best, M., Milev, R., Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J. Nerv. Ment. Dis. 201:8 (2013), 680–685, 10.1097/NMD.0b013e31829c5030.
7. Burdick, K.E., Endick, C.J., Goldberg, J.F., Assessing cognitive deficits in bipolar disorder: are self-reports valid?. Psychiatry Res. 136:1 (2005), 43–50, 10.1016/j.psychres.2004.12.009.
8. Carvalho, A.F., Miskowiak, K.K., Hyphantis, T.N., Kohler, C.A., Alves, G.S., Bortolato, B., McIntyre, R.S., Cognitive dysfunction in depression – pathophysiology and novel targets. CNS Neurol. Disord. Drug Targets 13:10 (2014), 1819–1835.
9. Culang, M., Sneed, J.R., Keilp, J.G., Rutherford, B.R., Pelton, G.H., Devanand, D.P., Roose, S.P., Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am. J. Geriatr. Psychiatry: Off. J. Am. Assoc. Geriatr. Psychiatry 17:10 (2009), 881–888.
10. DeBattista, C., Executive dysfunction in major depressive disorder. Expert Rev. Neurother. 5:1 (2005), 79–83, 10.1586/14737175.5.1.79.
11. Elgamal, S., MacQueen, G., Galantamine as an adjunctive treatment in major depression. J. Clin. Psychopharmacol. 28:3 (2008), 357–359, 10.1097/JCP.0b013e318172756c.
12. Ferguson, J.M., Wesnes, K.A., Schwartz, G.E., Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int. Clin. Psychopharmacol. 18:1 (2003), 9–14, 10.1097/01.yic.0000048749.53980.bf.
13. Fregni, F., Boggio, P.S., Nitsche, M.A., Rigonatti, S.P., Pascual-Leone, A., Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depress. Anxiety 23:8 (2006), 482–484, 10.1002/da.20201.
14. Georgotas, A., McCue, R.E., Reisberg, B., Ferris, S.H., Nagachandran, N., Chang, I., Mir, P., The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients. Int. Psychogeriatr./IPA 1:2 (1989), 135–143.
15. Glass, R.M., Uhlenhuth, E.H., Hartel, F.W., Matuzas, W., Fischman, M.W., Cognitive dysfunction and imipramine in outpatient depressive. Arch. General. Psychiatry 38:9 (1981), 1048–1051.
16. 3Gorwood et al., 2008 Gorwood, P., Corruble, E., Falissard, B., Goodwin, G.M., Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 165:6 (2008), 731–739, 10.1176/appi.ajp.2008.07040574.
17. Gualtieri, C.T., Morgan, D.W., The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J. Clin. Psychiatry 69:7 (2008), 1122–1130.
18. Guo, M., Mi, J., Jiang, Q.-M., Xu, J.-M., Tang, Y.-Y., Tian, G., Wang, B., Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 41:9 (2014), 650–656, 10.1111/1440-1681.12265.
19. Hasselbalch, B.J., Knorr, U., Kessing, L.V., Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J. Affect. Disord. 134:1–3 (2011), 20–31, 10.1016/j.jad.2010.11.011.
20. Hasselbalch, B.J., Knorr, U., Hasselbalch, S.G., Gade, A., Kessing, L.V., The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur. Psychiatry 28:6 (2013), 349–355, 10.1016/j.eurpsy.2012.03.004.
21. Hoffman, B.M., Blumenthal, J.A., Babyak, M.A., Smith, P.J., Rogers, S.D., Doraiswamy, P.M., Sherwood, A., Exercise fails to improve neurocognition in depressed middle-aged and older adults. Med. Sci. Sport. Exerc. 40:7 (2008), 1344–1352, 10.1249/MSS.0b013e31816b877c.
22. Holtzheimer, P.E., Meeks, T.W., Kelley, M.E., Mufti, M., Young, R., McWhorter, K., McDonald, W.M., A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int. J. Geriatr. Psychiatry 23:6 (2008), 625–631, 10.1002/gps.1951.
23. Jaeger, J., Berns, S., Uzelac, S., Davis-Conway, S., Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 145:1 (2006), 39–48, 10.1016/j.psychres.2005.11.011.
24. Jansen, W., Siegfried, K., Nomifensine in geriatric inpatients: a placebo-controlled study. J. Clin. Psychiatry 45:4 Pt 2 (1984), 63–67.
25. Jensen, J.H., Støttrup, M.M., Nayberg, E., Knorr, U., Ullum, H., Purdon, S.E., Miskowiak, K.W., Optimising screening for cognitive dysfunction in bipolar disorder: validation and evaluation of objective and subjective tools. J. Affect. Disord. 187 (2015), 10–19, 10.1016/j.jad.2015.07.039.
26. Judd, L.L., Akiskal, H.S., Maser, J.D., Zeller, P.J., Endicott, J., Coryell, W., Keller, M.B., Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. 50:2–3 (1998), 97–108.
27. Katona, C., Hansen, T., Olsen, C.K., A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 27:4 (2012), 215–223, 10.1097/YIC.0b013e3283542457.
28. Keefe, R.S.E., McClintock, S.M., Roth, R.M., Doraiswamy, P.M., Tiger, S., Madhoo, M., Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J. Clin. Psychiatry 75:8 (2014), 864–876, 10.4088/JCP.13r08609.
29. Kessing, L.V., Cognitive impairment in the euthymic phase of affective disorder. Psychol. Med. 28:5 (1998), 1027–1038.
30. Krogh, J., Saltin, B., Gluud, C., Nordentoft, M., The DEMO trial: a randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate sepression. J. Clin. Psychiatry 70:6 (2009), 790–800, 10.4088/JCP.08m04241.
31. Lavretsky, H., Alstein, L.L., Olmstead, R.E., Ercoli, L.M., Riparetti-Brown, M., Cyr, N.S., Irwin, M.R., Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. Am. J. Geriatr. Psychiatry: Off. J. Am. Assoc. Geriatr. Psychiatry 19:10 (2011), 839–850, 10.1097/JGP.0b013e31820ee9ef.
32. Lee, R.S.C., Hermens, D.F., Porter, M.A., Redoblado-Hodge, M.A., A meta-analysis of cognitive deficits in first-episode major depressive disorder. J. Affect. Disord. 140:2 (2012), 113–124, 10.1016/j.jad.2011.10.023.
33. Madhoo, M., Keefe, R.S., Roth, R.M., Sambunaris, A., Wu, J., Trivedi, M.H., Lasser, R., Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 39:6 (2014), 1388–1398, 10.1038/npp.2013.334.
34. Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Maj, M., The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24:1 (2009), 27–53, 10.1007/s11011-008-9118-1.
35. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S., A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40:8 (2015), 2025–2037, 10.1038/npp.2015.52.
36. McDermott, L.M., Ebmeier, K.P., A meta-analysis of depression severity and cognitive function. J. Affect. Disord. 119:1–3 (2009), 1–8, 10.1016/j.jad.2009.04.022.
37. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17:10 (2014), 1557–1567, 10.1017/S1461145714000546.
38. McIntyre, R.S., Cha, D.S., Soczynska, J.K., Woldeyohannes, H.O., Gallaugher, L.A., Kudlow, P., Baskaran, A., Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression Anxiety 30:6 (2013), 515–527, 10.1002/da.22063.
39. McIntyre, R.S., Xiao, H.X., Syeda, K., Vinberg, M., Carvalho, A.F., Mansur, R.B., Cha, D.S., The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 29:7 (2015), 577–589, 10.1007/s40263-015-0263-x.
40. Michalon, M., Eskes, G.A., Mate-Kole, C.C., Effects of light therapy on neuropsychological function and mood in seasonal affective disorder. J. Psychiatry Neurosci. 22:1 (1997), 19–28.
41. Miskowiak, K.W., Vinberg, M., Harmer, C.J., Ehrenreich, H., Kessing, L.V., Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology 219:3 (2012), 687–698, 10.1007/s00213-011-2511-1.
42. Miskowiak, K.W., Vinberg, M., Christensen, E.M., Bukh, J.D., Harmer, C.J., Ehrenreich, H., Kessing, L.V., Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 39:6 (2014), 1399–1408, 10.1038/npp.2013.335.
43. Miskowiak, K.W., Carvalho, A.F., Vieta, E., Kessing, L.V., Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol. 26(10), 2016a, 1541–61, 10.1016/j.euroneuro.2016.08.011.
44. Miskowiak, K.W., Petersen, J. Z., Ott, C.V., Knorr, U., Kessing, L.V., Gallagher, P., Robinson, L., 2016b. Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. ACTA Psychiatr. Scand. (in press).
45. Miskowiak, K.W., Rush, A.J., Gerds, T.A., Vinberg, M., Kessing, L.V., 2016c. Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. J. Clin. Psychiatry. (in press).
46. Mogg, A., Pluck, G., Eranti, S.V., Landau, S., Purvis, R., Brown, R.G., McLoughlin, D.M., A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. Psychol. Med. 38:3 (2008), 323–333, 10.1017/S0033291707001663.
47. Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., Altman, D.G., CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c869, 10.1136/bmj.c869.
48. Mohn, C., Rund, B.R., Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints. BMC Psychiatry, 16, 2016, 10.1186/s12888-016-0815-8.
49. Myint, A.M., Kim, Y.K., Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61:5–6 (2003), 519–525.
50. Nadeau, S.E., Bowers, D., Jones, T.L., Wu, S.S., Triggs, W.J., Heilman, K.M., Cognitive effects of treatment of depression with repetitive transcranial magnetic stimulation. Cogn. Behav. Neurol.: Off. J. Soc. Behav. Cogn. Neurol. 27:2 (2014), 77–87, 10.1097/WNN.0000000000000031.
51. Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D., Marder, S.R., The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165:2 (2008), 203–213, 10.1176/appi.ajp.2007.07010042.
52. Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H. –, Jönsson, B., The economic cost of brain disorders in Europe. Eur. J. Neurol. 19:1 (2012), 155–162, 10.1111/j.1468-1331.2011.03590.x.
53. Ott, C.V., Vinberg, M., Kessing, L.V., Miskowiak, K.W., The effect of erythropoietin on cognition in affective disorders – associations with baseline deficits and change in subjective cognitive complaints. Eur. Neuropsychopharmacol. 26:8 (2016), 1264–1273, 10.1016/j.euroneuro.2016.05.009.
54. Ott, C.V., Bjertrup, A.J., Jensen, J.H., Ullum, H., Sjælland, R., Purdon, S.E., Miskowiak, K.W., Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools. J. Affect. Disord. 190 (2016), 607–615, 10.1016/j.jad.2015.10.059.
55. Pehrson, A.L., Leiser, S.C., Gulinello, M., Dale, E., Li, Y., Waller, J.A., Sanchez, C., Treatment of cognitive dysfunction in major depressive disorder – a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 753 (2015), 19–31, 10.1016/j.ejphar.2014.07.044.
56. Pelton, G.H., Harper, O.L., Tabert, M.H., Sackeim, H.A., Scarmeas, N., Roose, S.P., Devanand, D.P., Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry 23:7 (2008), 670–676, 10.1002/gps.1958.
57. Purdon, S.E., The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties. 2005, PNL, Inc, Edmonton, Alberta, Canada.
58. Raskin, J., Wiltse, C.G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J.J., Mohs, R.C., Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 164:6 (2007), 900–909, 10.1176/ajp.2007.164.6.900.
59. Reichenberg, A., Harvey, P.D., Bowie, C.R., Mojtabai, R., Rabinowitz, J., Heaton, R.K., Bromet, E., Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 35:5 (2009), 1022–1029, 10.1093/schbul/sbn044.
60. Reynolds, C.F., Butters, M.A., Lopez, O., Pollock, B.G., Dew, M.A., Mulsant, B.H., DeKosky, S.T., Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch. General. Psychiatry 68:1 (2011), 51–60, 10.1001/archgenpsychiatry.2010.184.
61. Rock, P.L., Roiser, J.P., Riedel, W.J., Blackwell, A.D., Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 44:10 (2014), 2029–2040, 10.1017/S0033291713002535.
62. Roose, S.P., Sackeim, H.A., Krishnan, K.R.R., Pollock, B.G., Alexopoulos, G., Lavretsky, H., Old-Old Depression Study Group, Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am. J. Psychiatry 161:11 (2004), 2050–2059, 10.1176/appi.ajp.161.11.2050.
63. Rosa, A.R., Mercadé, C., Sánchez-Moreno, J., Solé, B., Mar Bonnin, C.D., Torrent, C., Martinez-Aran, A., Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J. Affect. Disord. 150:1 (2013), 29–36, 10.1016/j.jad.2013.02.022.
64. Rosenblat, J.D., Kakar, R., McIntyre, R.S., The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int. J. Neuropsychopharmacol., 19(2), 2016, pyv082, 10.1093/ijnp/pyv082.
65. Roth, M., Mountjoy, C.Q., Amrein, R., Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br. J. Psychiatry: J. Ment. Sci. 168:2 (1996), 149–157.
66. Snyder, H.R., Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol. Bull. 139:1 (2013), 81–132, 10.1037/a0028727.
67. Solé, B., Jiménez, E., Martinez-Aran, A., Vieta, E., Cognition as a target in major depression: new developments. Eur. Neuropsychopharmacol. 25:2 (2015), 231–247, 10.1016/j.euroneuro.2014.12.004.
68. Stage, F.K., Carter, H.C., Nora, A., Path analysis: an introduction and analysis of a decade of research. J. Educ. Res. 98:1 (2004), 5–12.
69. Triggs, W.J., Ricciuti, N., Ward, H.E., Cheng, J., Bowers, D., Goodman, W.K., Nadeau, S.E., Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 178:3 (2010), 467–474, 10.1016/j.psychres.2010.05.009.
70. Wolkenstein, L., Plewnia, C., Amelioration of cognitive control in depression by transcranial direct current stimulation. Biol. Psychiatry 73:7 (2013), 646–651, 10.1016/j.biopsych.2012.10.010.
71. Yatham, L.N., Torres, I.J., Malhi, G.S., Frangou, S., Glahn, D.C., Bearden, C.E., Chengappa, K.N.R., The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC): isbd-banc. Bipolar Disord. 12:4 (2010), 351–363, 10.1111/j.1399-5618.2010.00830.x.